Antibody Information

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

RG-7841 [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	17.76%
Patients Enrolled	Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, histologically or cytologically documented advanced or metastatic breast, ovarian, pancreatic, NSCLC, head and neck squamous cell carcinoma, or gastric cancer in dose escalation, adequate hematologic and end organ function, and measurable disease per RECIST v1.1.
Administration Dosage	Intravenously at doses of 0.20, 0.40, 0.80, 1.60, or 2.40 mg/kg once every 3 weeks (Q3W).
*Related Clinical Trial*
NCT Number	NCT02092792	Clinical Status	Phase 1
Clinical Description	A phase 1, open-label study evaluating the safety and tolerability of escalating doses of DLYE5953A in patients with refractory solid tumors.
Primary Endpoint	The confirmed overall objective response rate was 17.76%. All responders (8/68 patients) had PR,and all had received the RP2D dose of 2.40 mg/kg. This included three patients with MBC, and five patients in the NSCLC expansion cohort (5/25; 20%).
Other Endpoint	The recommended phase II dose (RP2D) was 2.40 mg/kg Q3W. No dose-limiting toxicities were identified during dose escalation (0.20-2.40 mg/kg; n = 20).

References

Ref 1	A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. Clin Cancer Res. 2020 Nov 1;26(21):5588-5597.